DuPont and DSM Announce Joint Venture in Surgical
DuPont and Royal DSM N.V. recently announced an agreement to form a joint venture (JV) to develop, manufacture and commercialize advanced surgical biomedical materials, pending European Union (EU) regulatory approval. The JV will be named Actamax Surgical Materials LLC. Under the JV agreement, DuPont and DSM will each share a 50% interest.
The JV will address the market for surgical sealants, adhesion barriers and tissue adhesives — a large and underserved market of more than 100 million annual surgical procedures worldwide. The outcome of many surgical procedures could be positively impacted using next-generation materials under development by the JV.
Actamax Surgical Materials LLC will build a comprehensive biomedical product portfolio based on several patent-protected biodegradable hydrogel technologies. The early technology development was completed using DuPont materials science and biotechnology capabilities. Commercialization will rely on the medical polymer processing and manufacturing capabilities of DSM.
“Our platform of technologies will offer physicians and patients improved outcomes of surgery that will prevent post-operative complications while reducing health care costs,” said John Ranieri, vice president – DuPont Applied BioSciences. “Actamax will deliver a number of science-based innovations that can be optimized for different surgical situations and clinical needs. The success DSM has had in the biomedical materials market makes them an ideal strategic partner for us to commercialize our technology portfolio.”
“The partnership with DuPont is a great way to further boost our activities in the biomedical field,” said Christophe Dardel, president – DSM Biomedical. “In line with our open innovation strategy, this will allow us to combine the strengths of two leading companies to develop solutions to better address patient needs through material innovations.”
Actamax Surgical Materials LLC is the newest offering from the DuPont Applied BioSciences (ABS) portfolio. ABS creates new disruptive technologies for large addressable markets utilizing biotechnology and other scientific tools. DuPont has launched several new ventures from the ABS business, including:
- DuPont Tate & Lyle BioProducts: the manufacturing and marketing arm for Bio-PDO®, the company's first biomaterial;
- DuPont Danisco Cellulosic Ethanol: the route to market for the integrated cellulosic ethanol technology package, developed jointly by DuPont and the Genencor division of Danisco;
- Butamax Advanced Biofuels LLC: the route to market for biobutanol, developed by DuPont with BP fuel, and fleet testing, as well as market access.
For more information, visit www.actamax.com.